STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #190 by analyst upside · 2026-06-27
BDTX
Black Diamond Therapeutics, Inc.
Healthcare · Market Cap $98M · P/E 0x
ANALYST PRICE TARGET
+476.4%
implied upside to consensus target
Current Price $1.71
Consensus Target $9.86
Bull Target $14.0
Bear Target $7.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
5
Hold
1
Sell
0
52-Week Low $1.6
52-Week High $4.94
YTD Return -31.3%
FUNDAMENTALS
Market Cap $98M
P/E Ratio (TTM) N/A
Forward P/E -1.5x
EPS (TTM) $-0.77
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.6
52-Week High $4.94
Current Price $1.71
Bear Target $7.0
Bull Target $14.0
● Now $1.71 ● Target $9.86
TRADING DATA
Avg Volume 1.6M
YTD Return -31.3%
Analyst Count 7
Consensus Buy
Upside to Target +476.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Black Diamond Therapeutics, Inc. (BDTX) is currently trading at $1.71 with a Wall Street consensus price target of $9.86, implying potential upside of 476.4% over the next 12 months. 7 analysts currently cover BDTX, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $7.0.

BDTX operates in the Healthcare sector with a market capitalisation of $98M. The stock is down 31.3% year-to-date and is currently trading near the lower end of its 52-week range of $1.6 – $4.94.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BDTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG — Reiterated
Buy → Buy 2026-04-29 38% win rate (8 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-03-17 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-01-16 14% win rate (7 calls)
Guggenheim ↓ Downgrade
Buy → Neutral 2025-12-04 62% win rate (8 calls)
Freedom Broker ● Initiated
Buy 2025-10-01 Building track record
Guggenheim ● Initiated
Buy 2025-09-04 62% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-08-11 31% win rate (48 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-03-18 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →